Trial Profile

A Phase II Study of the Safety, Tolerability and Antitumor Activity of Tucatinib in Combination with Eribulin and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eribulin (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary)
Indications Advanced breast cancer; Carcinoma; HER2 positive breast cancer; Male breast cancer
Focus Adverse reactions
Sponsors Criterium

08 Mar 2024 Planned End Date changed from 26 May 2025 to 1 Aug 2027.
08 Mar 2024 Planned primary completion date changed from 26 Nov 2023 to 1 Jun 2027.
05 Jan 2023 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com